Revised Terminology on Sepsis

  • J.-L. Vincent
Conference paper


Over recent years, major advances have been made in our understanding of the sepsis response, its origins, mediators, effects, and consequences. Ongoing research continues to add to our knowledge of this complex and complicated process. Sepsis is the systemic response to infection, but as it emerged that the inflammatory response which is aroused in sepsis can also occur in conditions in which infection is not apparent, attempts were made to introduce new terminology to define and label these conditions. Terms such as the sepsis syndrome [1] and the systemic inflammatory response syndrome (SIRS) [2] became popular and have been used widely in describing patients both individually and in larger groups for clinical trial purposes.


Systemic Inflammatory Response Syndrome Septic Patient Meningococcal Disease Sepsis Syndrome Systemic Inflammatory Response Syndrome Criterion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bone RC, Fisher CJJ, Clemmer TP et al (1989) Sepsis syndrome: a valid clinical entity. Methylprednisolone Severe Sepsis Study Group. Crit Care Med 17:389–393PubMedCrossRefGoogle Scholar
  2. 2.
    Anonymous (1992) American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20:864–874Google Scholar
  3. 3.
    Ford EG, Baisden CE, Matteson ML, Picone AL (1991) Sepsis after coronary bypass grafting: evidence for loss of the gut mucosal barrier. Ann Thorac Surg 52:514–517PubMedCrossRefGoogle Scholar
  4. 4.
    Brathwaite CE, Ross SE, Nagele R et al (1993) Bacterial translocation occurs in humans after traumatic injury: evidence using immunofluorescence. J Trauma 34:586–589PubMedCrossRefGoogle Scholar
  5. 5.
    Vincent JL (1997) Dear SIRS, I’m sorry to say that I don’t like you. Crit Care Med 25: 372–374PubMedCrossRefGoogle Scholar
  6. 6.
    Rangel-Frausto MS, Pittet D, Costigan M et al (1995) The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 273:117–123PubMedCrossRefGoogle Scholar
  7. 7.
    Bossink AW, Groeneveld J, Hack CE, Thijs LG (1998) Prediction of mortality in febrile medical patients: How useful are systemic inflammatory response syndrome and sepsis criteria? Chest 113:1533–1541PubMedCrossRefGoogle Scholar
  8. 8.
    Opal SM (1998) The uncertain value of the definition for SIRS, Systemic inflammatory response syndrome. Chest 113:1442–1443PubMedCrossRefGoogle Scholar
  9. 9.
    Clemmer TP, Fisher CJJ, Bone RC et al (1992) Hypothermia in the sepsis syndrome and clinical outcome. The Methylprednisolone Severe Sepsis Study Group. Crit Care Med 20: 1395–1401PubMedCrossRefGoogle Scholar
  10. 10.
    Pinsky MR, Vincent JL, Deviere J et al (1993) Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest 103:565–575PubMedCrossRefGoogle Scholar
  11. 11.
    Damas P, Canivet JL, de Groote D et al (1997) Sepsis and serum cytokine concentrations. Crit Care Med 25:405–412PubMedCrossRefGoogle Scholar
  12. 12.
    Reinhart K, Ramses Study Group (1998) Treatment of severe sepsis in patients with highly elevated IL-6 levels with anti-TNF monoclonal antibody MAK 195F. Crit Care 2:P18 (abstract)CrossRefGoogle Scholar
  13. 13.
    Ertel W, Keel M, Bonaccio M et al (1995) Release of anti-inflammatory mediators after mechanical trauma correlates with severity of injury and clinical outcome. J Trauma 39:879–885PubMedCrossRefGoogle Scholar
  14. 14.
    Brivet FG, Emilie D, Galanaud P (1999) Pro- and anti-inflammatory cytokines during acute severe pancreatitis: an early and sustained response, although unpredictable of death. Parisian Study Group on Acute Pancreatitis. Crit Care Med 27:749–755PubMedCrossRefGoogle Scholar
  15. 15.
    Matson A, Soni N, Sheldon J (1991) C-reactive protein as a diagnostic test of sepsis in the critically ill. Anaesth Intensive Care 19:182–186PubMedGoogle Scholar
  16. 16.
    Povoa P, Almeida E, Moreira P et al (1998) C-reactive protein as an indicator of sepsis. Intensive Care Med 24:1052–1056PubMedCrossRefGoogle Scholar
  17. 17.
    Yentis SM, Soni N, Sheldon J (1995) C-reactive protein as an indicator of resolution of sepsis in the intensive care unit. Intensive Care Med 21:602–605PubMedCrossRefGoogle Scholar
  18. 18.
    Nijsten MWN, Olinga P, The TH (1999) Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro. Crit Care Med (in press)Google Scholar
  19. 19.
    Whang KT, Vath SD, Nylen ES et al (1999) Procalcitonin and proinflammatory cytokine in interactions in sepsis. Shock 12:268–273PubMedCrossRefGoogle Scholar
  20. 20.
    Nylen ES, Whang KT, Snider RHJ et al (1998) Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis [see comments]. Crit Care Med 26:1001–1006PubMedCrossRefGoogle Scholar
  21. 21.
    Hammer S, Meisner F, Dirschedl P et al (1998) Procalcitonin: a new marker for diagnosis of acute rejection and bacterial infection in patients after heart and lung transplantation. Transpl Immunol 6:235–241PubMedCrossRefGoogle Scholar
  22. 22.
    Rothenburger M, Markewitz A, Lenz T et al (1999) Detection of acute phase response and infection. The role of procalcitonin and C-reactive protein. Clin Chem Lab Med 37:275–279PubMedCrossRefGoogle Scholar
  23. 23.
    Müller B, Becker KL, Schächinger H et al (1999) Procalcitonin peptides are reliable markers of sepsis in a medical intensive care unit. Crit Care Med (in press)Google Scholar
  24. 24.
    Oberhoffer M, Karzai W, Meier-Hellmann A et al (1999) Sensitivity and specificity of various markers of inflammation for the prediction of tumor necrosis factor-alpha and interleukin-6 in patients with sepsis. Crit Care Med 27:1814–1818PubMedCrossRefGoogle Scholar
  25. 25.
    Schroder J, Staubach KH, Zabel P et al (1999) Procalcitonin as a marker of severity in septic shock. Langenbecks Arch Surg 384:33–38PubMedCrossRefGoogle Scholar
  26. 26.
    Ugarte H, Silva E, Mercan D et al (1999) Procalcitonin used as a marker of infection in the intensive care unit. Crit Care Med 27:498–504PubMedCrossRefGoogle Scholar
  27. 27.
    Pacher R, Redl H, Frass M et al (1989) Relationship between neopterin and granulocyte elastase plasma levels and the severity of multiple organ failure. Crit Care Med 17:221–226PubMedCrossRefGoogle Scholar
  28. 28.
    Yao YM, Yu Y, Wang YP et al (1996) Elevated serum neopterin level: its relation to endotoxaemia and sepsis in patients with major burns. Eur J Clin Invest 26:224–230PubMedCrossRefGoogle Scholar
  29. 29.
    Nyman KM, Uhl W, Forsstrom J et al (1996) Serum phospholipase A2 in patients with multiple organ failure. J Surg Res 60:7–14PubMedCrossRefGoogle Scholar
  30. 30.
    Vincent JL (1999) Procalcitonin: the marker of sepsis? Crit Care Med (in press)Google Scholar
  31. 31.
    Opal SM, Fisher CJJ, Dhainaut JF et al (1997) Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 25:1115–1124PubMedCrossRefGoogle Scholar
  32. 32.
    Abraham E, Anzueto A, Gutierrez G et al (1998) Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. Norasept II Study Group. Lancet 351:929–933PubMedGoogle Scholar
  33. 33.
    Dhainaut JF, Tenaillon A, Hemmer M et al (1998) Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group. Crit Care Med 26:1963–1971PubMedCrossRefGoogle Scholar
  34. 34.
    Wasserman D, Ioannovich JD, Hinzmann RD et al (1998) Interferon-gamma in the prevention of severe burn-related infections: a European phase III multicenter trial. The Severe Burns Study Group. Crit Care Med 260:434–439CrossRefGoogle Scholar
  35. 35.
    Vincent JL (1997) New therapies in sepsis. Chest 112:330S–338SPubMedCrossRefGoogle Scholar
  36. 36.
    Vincent JL (1999) The immune response in critical illness: Excessive, inadequate or dysregulated. In: Marshall JC, Cohen J (eds) Immune Response in the Critically Ill. Springer, Heidelberg, pp 12–21Google Scholar
  37. 37.
    Docke WD, Randow F, Syrbe U et al (1997) Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 3:678–681PubMedCrossRefGoogle Scholar
  38. 38.
    Stuber F, Petersen M, Bokelmann F, Schade U (1996) A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis [see comments]. Crit Care Med 24:381–384PubMedCrossRefGoogle Scholar
  39. 39.
    Hermans PW, Hibberd ML, Booy R et al (1999) 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group. Lancet 354:556–560PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2000

Authors and Affiliations

  • J.-L. Vincent

There are no affiliations available

Personalised recommendations